Dr. Lynn Connolly is chief medical officer with more than 20 years of experience in infectious diseases, including more than 12 years of experience in anti-infective drug development.
Prior to joining Qpex, Lynn held leadership positions at AN2 Therapeutics, Adagio Therapeutics (now Invivyd), Vir Biotechnology and Achaogen. At these firms, she guided the clinical development of therapeutic agents for treatment of bacterial and viral infections, including the completion of Phase 3 studies and FDA approval of the antibiotic plazomicin for cUTIs and the Phase 1 through 3 global development of adintrevimab for treatment and prevention of COVID-19.
Prior to her career in industry, Lynn was a member of the infectious disease faculty at the University of California San Francisco (UCSF) and the University of Washington. She is an inventor on five patents and patent applications and has authored 30 original papers, review articles and book chapters. Lynn completed undergraduate work at the University of California Berkeley, MD and Ph.D. degrees at UCSF, residency in internal medicine at Stanford University Hospital and infectious disease fellowship at the University of Washington.
